A Phase 1, Open Label, Multi-Center, Accelerated Dose-Escalation, Pharmacokinetic And Pharmacodynamic Trial Of The Oral Single Agent Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors For Whom No Standard Therapy Is Available.
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2012
At a glance
- Drugs PF 3814735 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 Jun 2012 Actual patient number is 57 according to ClinicalTrials.gov.
- 28 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2009 Planned end date changed from 1 Sep 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.